HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $36.00 price target on the stock. A number of other equities analysts have also weighed in on FDMT. Royal […]
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $36.00 price target on the stock. A number of other equities analysts have also weighed in on FDMT. Royal […]
